ArticleThe Journal of experimental medicine2010
ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo.
Article in The Journal of experimental medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 149 citations in OpenAlex.
- The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2015Trial
- B cell-intrinsic Ssu72 phosphatase is a key regulator of allergic asthma.Experimental & molecular medicine · 2026Article
- B1 cells drive pulmonary emphysema progression through ADAM10.Respiratory research · 2026Article
- Tetraspanins 10 and 15 support Venezuelan equine encephalitis virus replication in astrocytoma cells.Molecular biology of the cell · 2025Article
- Progression of Notch signaling regulation of B cells under radiation exposure.Frontiers in immunology · 2024Review
- On the complexity of IgE: The role of structural flexibility and glycosylation for binding its receptors.Frontiers in allergy · 2023Review
- Identification and characterization of enhancer elements controlling cell type-specific and signalling dependent chromatin programming during hematopoietic development.Stem cell investigation · 2023Review
- Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas.Signal transduction and targeted therapy · 2022Article
- Immunomodulatory role of metalloproteases in cancers: Current progress and future trends.Frontiers in immunology · 2022Review
- Article
- Abnormal B-cell development in TIMP-deficient bone marrow.Blood advances · 2021Article
- Tuning IgE: IgE-Associating Molecules and Their Effects on IgE-Dependent Mast Cell Reactions.Cells · 2021Review
- Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens.PLoS pathogens · 2021Article
- Gene expression in tonsils in swine following infection with porcine reproductive and respiratory syndrome virus.BMC veterinary research · 2021Article
- IRF4 Has a Unique Role in Early B Cell Development and Acts Prior to CD21 Expression to Control Marginal Zone B Cell Numbers.Frontiers in immunology · 2021Article
- TAO-kinase 3 governs the terminal differentiation of NOTCH2-dependent splenic conventional dendritic cells.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- Mechanoregulation in hematopoiesis and hematologic disorders.Current stem cell reports · 2020Article
- B cell ADAM17 controls T cell independent humoral immune responses through regulation of TACI and CD138.Biochemical and biophysical research communications · 2020Article
- Notch Signaling in B Cell Immune Responses.Frontiers in immunology · 2020Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
The proteolytic activity of a disintegrin and metalloproteinase 10 (ADAM10) regulates cell-fate decisions in Drosophila and mouse embryos. However, in utero lethality of ADAM10(-/-) mice has prevented examination of ADAM10 cleavage events in lymphocytes. To investigate their role in B cell development, we generated B cell-specific ADAM10 knockout mice. Intriguingly, deletion of ADAM10 prevented development of the entire marginal zone B cell (MZB) lineage. Additionally, cleavage of the low affinity IgE receptor, CD23, was profoundly impaired, but subsequent experiments demonstrated that ADAM10 regulates CD23 cleavage and MZB development by independent mechanisms. Development of MZBs is dependent on Notch2 signaling, which requires proteolysis of the Notch2 receptor by a previously unidentified proteinase. Further experiments revealed that Notch2 signaling is severely impaired in ADAM10-null B cells. Thus, ADAM10 critically regulates MZB development by initiating Notch2 signaling. This study identifies ADAM10 as the in vivo CD23 sheddase and an important regulator of B cell development. Moreover, it has important implications for the treatment of numerous CD23- and Notch-mediated pathologies, ranging from allergy to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.